How to administer Ambisome (amphotericin B liposomal)

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Administration of AmBisome (Liposomal Amphotericin B)

Liposomal amphotericin B (AmBisome) should be administered intravenously at a dose of 3-5 mg/kg daily for standard fungal infections, with premedication to prevent infusion-related reactions and adequate hydration to minimize nephrotoxicity. 1, 2

Preparation and Administration

  • Reconstitute AmBisome by adding 12 mL of sterile water for injection to each 50 mg vial, creating a concentration of 4 mg/mL 2
  • Shake the vial vigorously for at least 30 seconds until all material is completely dispersed 3
  • Further dilute the reconstituted solution with 5% dextrose injection to a final concentration of 1-2 mg/mL before administration 2
  • Administer through an in-line filter with a mean pore diameter of 1.0 micron or larger 3
  • Infuse over 1-2 hours; longer infusion times may be used for patients who experience infusion-related reactions 1

Premedication and Hydration

  • Administer premedication with diphenhydramine or acetaminophen 30 minutes before infusion to reduce infusion-related reactions 2, 3
  • Provide 1 L of normal saline (0.9%) intravenously before AmBisome infusion to reduce nephrotoxicity in patients who can tolerate the fluid volume 1, 2
  • Consider additional 1 L of normal saline after infusion to further minimize nephrotoxicity 2

Dosing by Indication

  • For cryptococcal meningitis: 4-6 mg/kg daily 4
  • For severe or life-threatening fungal infections: 5 mg/kg daily 1
  • For CNS involvement: Higher doses of 5-10 mg/kg daily may be required 2
  • For children with cryptococcal meningitis: 2 mg/kg daily, with doses up to 7.5 mg/kg daily for refractory cases 4

Monitoring During Therapy

  • Monitor renal function, electrolytes, and liver function tests regularly 1, 3
  • Watch for infusion-related reactions including chest pain, dyspnea, hypoxia, severe abdominal/flank/leg pain, flushing, and urticaria 4
  • If infusion reactions occur, temporarily interrupt the infusion and administer intravenous diphenhydramine 4
  • For persistent fungal infections despite therapy, investigate for deep tissue focus of infection 3

Special Considerations

  • Do not confuse AmBisome (liposomal amphotericin B) with conventional amphotericin B deoxycholate (Fungizone), as this can lead to serious toxicity due to significant dosing differences 5
  • AmBisome has significantly less nephrotoxicity than conventional amphotericin B deoxycholate, allowing for higher dosing 6
  • For patients with renal impairment, AmBisome is preferred over conventional amphotericin B 4
  • Duration of therapy depends on the specific infection being treated, but typically continues until clinical and microbiological resolution 1

Common Pitfalls and Caveats

  • Avoid rapid infusion, which can increase the risk of infusion-related reactions 3
  • Never substitute different formulations of amphotericin B (liposomal, lipid complex, colloidal dispersion, or conventional) without appropriate dose adjustments 5
  • Do not mix or co-infuse with other medications or electrolyte solutions 3
  • Store unopened vials at refrigerated temperature (2-8°C) and protect from light 3
  • Reconstituted solution can be stored for up to 24 hours at 2-8°C 3

References

Guideline

Amphotericin B Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Liposomal Amphotericin B Treatment for Severe Fungal Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Administration Protocol for Lyophilized Amphotericin B

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.